Stentys SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Stentys SA's Self-Apposing Stent Demonstrates Lowest Mortality Rate Among Large Heart Attack Trials
Stentys SA announced one-year results of the APPOSITION III clinical trial in 1,000 patients post treatment of a severe heart attack at ACC.13, the American College of Cardiology’s Scientific Session & Expo. The APPOSITION III trial is a prospective, single-arm, multi-center study designed to assess the long term performance of STENTYS Self-Apposing Stents in routine clinical practice in Europe among patients suffering from ST-elevation myocardial infarction (STEMI). The primary endpoint, Major Adverse Cardiac Events rate (MACE, defined as cardiac death, target vessel re-MI, emergent by-pass, or clinically-driven TVR) at one year, was 9.3%, where conventional stents average 11.1% in a pooled analysis from ACTION Study Group (Pitié-Salpêtrière Hospital, Paris). At the one-year time point, the cardiac death rate was 2.0%, as compared with rates for conventional stents in other published trials which average 3.9%, the lowest rate being 2.2%.
Latest Developments for Stentys SA
- Stentys SA Announces Positive Results of Its OPEN II study of Self-Apposing Stent
- Stentys SA Sirolimus-Eluting Stent Demonstrates Faster Arterial Healing Than Conventional Drug-Eluting Stent
- Stentys SA Receives Approval to Expand CE Mark Indications of Its Self-Apposing Stent-DJ
- Stentys SA Announces Positive Interim Results of APPOSITION III Clinical Trial of STENTYS Self-Apposing Stents
Latest Key Developments in Medical
- Share this
- Digg this